BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.08
+0.18 (2.61%)
At close: Nov 14, 2025, 4:00 PM EST
7.05
-0.03 (-0.42%)
After-hours: Nov 14, 2025, 7:00 PM EST
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $159.40M in the quarter ending September 30, 2025, with 36.14% growth. This brings the company's revenue in the last twelve months to $599.82M, up 45.38% year-over-year. In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth.
Revenue (ttm)
$599.82M
Revenue Growth
+45.38%
P/S Ratio
2.47
Revenue / Employee
$1,034,166
Employees
580
Market Cap
1.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
| Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
| Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
| Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
| Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BCRX News
- 9 days ago - BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat) - GlobeNewsWire
- 10 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - BioCryst to Present at Upcoming Investor Conference - GlobeNewsWire
- 12 days ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - GlobeNewsWire
- 26 days ago - BioCryst to Report Third Quarter 2025 Financial Results on November 3 - GlobeNewsWire
- 4 weeks ago - Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - Business Wire